Share:
RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE)
MobileSmith Health (OTC:MOST), a leader in the digital health and mobile development sector who is changing traditional healthcare patient engagement and adherence management, today announced the establishment of its Product Advisory Board (PAB). The PAB will provide advice to the executive management team on the company s software products, including feedback on features and capabilities, audience targeting, competition, major industry trends and other related issues. At MobileSmith, we strive to ensure our products are effective in bridging the gap between providers and patients, and patients and their health. The establishment of the Product Advisory Board gives us an unmatched insight from the doctors, nurses, patient advocates and other hospital staff who are on the frontlines of healthcare, said Les Jordan, MobileSmith Health s chief product and strategy officer. We re thrilled to welcome the Board Members as a par
How do I know if I am a good mother?
Throughout high school, college, and medical school, I chased after positive praise in the form of honor rolls, accolades, and awards. With hard work and a type A personality, I collected them, each form of external validation a sort of feather in my cap. A cap that was never complete, but in constant need of bigger, more colorful feathers. I ultimately chose a career in surgery because as a surgeon, immediate feedback is abundant. A lot of it is negative, but at least it is obvious where one stands.
During the 9 years I spent as a surgical trainee, I grew so accustomed to criticism that the absence of it was itself a form of praise. In residency, we joked that if one of the grouchy attending surgeons let out fewer than 5 exasperated sighs during an operation with us, we had succeeded. Frequent nitpicking and reprimand became comfortable and familiar, sporadic praise an unexpected delight.
E-Mail
SAN ANTONIO (May 4, 2021) - Risk-reducing mastectomy saves lives of women who, because of hereditary or other risk factors, may have a very high lifetime risk of developing breast cancer, according to two new journal articles written to guide physicians and patients. All of these women should also discuss with their physicians nonsurgical options such as screening and medications to reach the best, customized treatment strategy, the essays mention.
Both articles, published May 4 in the
Journal of the American Medical Association (JAMA), are by Ismail Jatoi, MD, PhD, of The University of Texas Health Science Center at San Antonio (also called UT Health San Antonio) and Zoe Kemp, MD, PhD, of the Royal Marsden Hospital in London, England.
New study launched to more accurately diagnose early hepatocellular carcinoma
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual s likelihood of developing the cancer. HCC is the sixth most common cancer in the world but the third most common cause of cancer deaths globally. In Singapore, HCC is the third and fourth most common cause of cancer deaths, amongst males and females respectively.
While potentially curative treatment is possible with early diagnosis, only 20% of HCC cases are detected at a stage where cure is possible. This investigator-initiated multi-centre study led by the National Cancer Centre of Singapore (NCCS) called EarLy DEtection of HCC: miRNA, microbiome and imaGing biomArkers in the evolution of chroNiC livEr Disease in a high-risk prospective cohort (ELEGANCE), addresses thi
E-Mail
IMAGE: Quantitative MR images of the liver from six patients presenting with liver cancer produced by Perspectum s LiverMultiScan which will be used in a new study led by National Cancer Centre. view more
Credit: Image credit: Mole DJ et al. Plos One. 2020;15(12):e0238568
Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.
Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual s risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.